<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117713</url>
  </required_header>
  <id_info>
    <org_study_id>LUM001-305</org_study_id>
    <secondary_id>SHP625-305</secondary_id>
    <nct_id>NCT02117713</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome</brief_title>
  <acronym>IMAGINE-II</acronym>
  <official_title>A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lumena Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Childhood Liver Disease Research and Education Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome&#xD;
      who have completed participation in a core LUM001 treatment protocol. The primary objective&#xD;
      is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by&#xD;
      evaluating the effect of LUM001 on the biochemical markers and pruritus associated with&#xD;
      Alagille Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2015</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 218 in Pruritus</measure>
    <time_frame>Baseline to Week 218</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 216 in Alanine Aminotransferase</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Alkaline Phosphatase</measure>
    <time_frame>Baseline to Week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From MRX Baseline to Week 216 in Aspartate Aminotransferase</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score</measure>
    <time_frame>Baseline to Week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase</measure>
    <time_frame>Baseline to Week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From MRX Baseline to Week 216 in Total Bilirubin</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From MRX Baseline to Week 216 in Direct Bilirubin</measure>
    <time_frame>Baseline to week 216</time_frame>
    <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alagille Syndrome</condition>
  <arm_group>
    <arm_group_label>LUM001 (Maralixibat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUM001 (Maralixibat)</intervention_name>
    <description>Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).</description>
    <arm_group_label>LUM001 (Maralixibat)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 12 months to 18 years of age.&#xD;
&#xD;
          2. Competent to provide informed consent and assent (per institutional review&#xD;
             board/Ethics Committee [IRB/EC]), as appropriate.&#xD;
&#xD;
          3. Completed participation in the LUM001-301 protocol.&#xD;
&#xD;
          4. Females of childbearing potential must have a negative urine pregnancy test [beta&#xD;
             human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.&#xD;
&#xD;
          5. Sexually active females must be prepared to use an effective method of contraception&#xD;
             during the trial.&#xD;
&#xD;
             Effective methods of contraception are considered to be:&#xD;
&#xD;
               1. Hormonal (for example, contraceptive pill, patch, intramuscular implant or&#xD;
                  injection); or&#xD;
&#xD;
               2. Barrier method, for example, (a) condom with spermicide, or (b) diaphragm, with&#xD;
                  spermicide; or&#xD;
&#xD;
               3. Intrauterine device (IUD).&#xD;
&#xD;
          6. Participants above the age of assent and caregivers and children must be able to read&#xD;
             and understand English or Spanish.&#xD;
&#xD;
          7. Caregivers (and age appropriate participants) must have access to phone for scheduled&#xD;
             calls from study site.&#xD;
&#xD;
          8. Caregivers (and age appropriate participants) must be willing and able to complete a&#xD;
             daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and&#xD;
             then for 4 consecutive weeks following the Week 24 and Week 44 visits.&#xD;
&#xD;
          9. Caregivers (and age appropriate participants) must digitally accept the licensing&#xD;
             agreement in the ItchRO electronic diary software at the outset of the study.&#xD;
&#xD;
         10. Eligible participants must be able to adhere to local Ethics Committee or&#xD;
             Institutional Review Board (IRB) blood volume limits for laboratory testing.&#xD;
&#xD;
         11. The participant has completed the protocol either through Week 144, or the End of&#xD;
             Trial visit, or has received permission from the sponsor and the Premier Medical&#xD;
             monitor to re-enter the study in the long-term, optional follow-up treatment period 2.&#xD;
&#xD;
         12. Females of child-bearing potential must have a negative urine or serum pregnancy test&#xD;
             (beta-HCG]) at the time of entry into the long-term optional follow-up treatment&#xD;
             period 2.&#xD;
&#xD;
         13. Male and female participants of child-bearing potential who are sexually active, or&#xD;
             are not currently sexually active, but become sexually active during the study or for&#xD;
             30 days following the last dose of study drug, must agree to use acceptable&#xD;
             contraception during the study.&#xD;
&#xD;
         14. Informed consent and assent (per IRB/EC) as appropriate.&#xD;
&#xD;
         15. Caregivers (and age appropriate participants) must have access to phone for scheduled&#xD;
             calls from study site.&#xD;
&#xD;
         16. Caregivers (and age appropriate participants) must be willing to follow the rules of&#xD;
             eDiary completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Experienced an adverse event or serious adverse event (SAE) related to the study drug&#xD;
             during the LUM001-301 protocol that led to the discontinuation of the participant from&#xD;
             the core study.&#xD;
&#xD;
          2. Any conditions or abnormalities (including laboratory abnormalities) which in the&#xD;
             opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may&#xD;
             compromise the safety of the participant, or interfere with the participant&#xD;
             participating in or completing the study.&#xD;
&#xD;
          3. History or known presence of gallstones or kidney stones.&#xD;
&#xD;
          4. History of non-adherence during the participant's participation in the LUM001-301&#xD;
             protocol. Non-adherence is defined by dosing compliance (dosing compliance is&#xD;
             calculated by [the total number of doses that were actually taken by the participant]&#xD;
             divided by [the total number of doses that should have been taken by the participant]&#xD;
             multiplied by 100) of less than 80% in the LUM001-301 protocol.&#xD;
&#xD;
          5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as&#xD;
             judged by the investigator.&#xD;
&#xD;
          6. All above exclusion criteria will apply upon re-entry into the long-term, optional&#xD;
             follow-up treatment period 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Mirum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>May 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02117713/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02117713/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LUM001 (Maralixibat)</title>
          <description>Participant received LUM001 also known as Maralixibat (MRX) administered orally once per day for up to 216 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by caregiver</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not consent to Protocol Amendment 4</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long Term Follow-up Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In the lead-in Study LUM001-301, participants were randomized to receive either placebo or active drug (MRX). The last observation obtained before first dose of MRX (either for participants who received MRX or placebo LUM001-301) was used as the MRX baseline observation for all calculations of change. For participants who were assigned MRX in LUM001-301, results at each post-baseline analysis visit included up to 13 more weeks of treatment than participants who were assigned placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Core Study Period</title>
          <description>Participant received LUM001 also known as Maralixibat (MRX) administered orally once per day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years of age</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)</title>
        <description>This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Maralixibat Week 48 Values</title>
            <description>Week 48 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)</title>
          <description>This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.62" spread="205.041"/>
                    <measurement group_id="O2" value="157.35" spread="178.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test used to test if mean change is statistically significant; null hypothesis is that the mean change from baseline is equal to zero.</non_inferiority_desc>
            <p_value>0.1157</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-28.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>89.456</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.72</ci_lower_limit>
            <ci_upper_limit>7.54</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 48 values for n= 26</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)</title>
        <description>The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Maralixibat Baseline Values</title>
            <description>These are the MRX baseline values for participants.</description>
          </group>
          <group group_id="O2">
            <title>Week 216</title>
            <description>These are the week 216 values of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)</title>
          <description>The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.62" spread="205.041"/>
                    <measurement group_id="O2" value="118.81" spread="126.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test used to test if mean change is statistically significant; null hypothesis is that the mean change from baseline is equal to zero.</non_inferiority_desc>
            <p_value>0.1469</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-45.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>89.934</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.48</ci_lower_limit>
            <ci_upper_limit>19.19</ci_upper_limit>
            <other_analysis_desc>Difference is only calculated in participants who had baseline and week 216 values for n=10</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 218 in Pruritus</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.</description>
        <time_frame>Baseline to Week 218</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Maralixibat Baseline Values</title>
            <description>These are the MRX baseline values for participants.</description>
          </group>
          <group group_id="O2">
            <title>Week 218</title>
            <description>These are values from Week 218.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 218 in Pruritus</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.533" spread="0.8423"/>
                    <measurement group_id="O2" value="0.429" spread="0.8571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.353</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.7124</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.101</ci_lower_limit>
            <ci_upper_limit>-1.606</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 218 values for n=6</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 216 in Alanine Aminotransferase</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216 Values</title>
            <description>These are the week 216 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 216 in Alanine Aminotransferase</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.9" spread="82.26"/>
                    <measurement group_id="O2" value="222.4" spread="126.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.2607</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>56.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>119.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.4</ci_lower_limit>
            <ci_upper_limit>166.4</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Alkaline Phosphatase</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.</description>
        <time_frame>Baseline to Week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216 Values</title>
            <description>These are the 2616 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Alkaline Phosphatase</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598.8" spread="199.89"/>
                    <measurement group_id="O2" value="528.3" spread="221.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.1340</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-141.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>216.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-341.6</ci_lower_limit>
            <ci_upper_limit>58.4</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From MRX Baseline to Week 216 in Aspartate Aminotransferase</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216</title>
            <description>These are the week 216 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From MRX Baseline to Week 216 in Aspartate Aminotransferase</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.7" spread="88.27"/>
                    <measurement group_id="O2" value="231.4" spread="122.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.1474</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>47.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>75.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.4</ci_lower_limit>
            <ci_upper_limit>117.6</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216</title>
            <description>These are the week 216 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>Points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.33"/>
                    <measurement group_id="O2" value="1.1" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>1.00</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.</description>
        <time_frame>Baseline to Week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216</title>
            <description>These are the week 216 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>Points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.08"/>
                    <measurement group_id="O2" value="1.1" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test used to test if mean change is statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.0167</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.</description>
        <time_frame>Baseline to Week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216 Values</title>
            <description>These are the week 216 values of the participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493.5" spread="380.29"/>
                    <measurement group_id="O2" value="431" spread="235.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.9108</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>245.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-216.6</ci_lower_limit>
            <ci_upper_limit>238.3</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From MRX Baseline to Week 216 in Total Bilirubin</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216</title>
            <description>These are the week 216 values for participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From MRX Baseline to Week 216 in Total Bilirubin</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="6.420"/>
                    <measurement group_id="O2" value="5.39" spread="5.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant(null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.1207</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1207</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.882</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From MRX Baseline to Week 216 in Direct Bilirubin</title>
        <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.</description>
        <time_frame>Baseline to week 216</time_frame>
        <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MRX Baseline Value</title>
            <description>These are the MRX baseline values for participants</description>
          </group>
          <group group_id="O2">
            <title>Week 216 Values</title>
            <description>These are the week 216 values of the participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From MRX Baseline to Week 216 in Direct Bilirubin</title>
          <description>This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.</description>
          <population>Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.541" spread="3.6433"/>
                    <measurement group_id="O2" value="3.714" spread="3.8369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Student's t-test was used to test if mean change was statistically significant (null hypothesis is that the mean change from baseline is equal to zero).</non_inferiority_desc>
            <p_value>0.0927</p_value>
            <method>Student's t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.943</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.2488</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.098</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Difference is only calculated in participants who had baseline and week 216 values for n=7</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to End of Treatment (Week 216)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LUM001 (Maralixibat)</title>
          <description>Participant received LUM001 (also known as Maralixibat or MRX) as oral solution once daily based on participant's weight. The dose was escalated from 14, 35, 70, 140 and 280 microgram per kilogram per day (mcg/kg/day) for 4-week dose escalation period. During 8-weeks of dose optimization period, drug was adjusted in titrated manner and dosing was continued to complete the stable dosing and safety monitoring periods for up to 96 weeks of cumulative LUM001 exposure in this study. Dosing during long-term optional follow-up treatment periods 1 and 2 was maintained at the same dose levels as at weeks 96 and 144 for participants rolling over into these treatment periods respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v.22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v.22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Bicuspid aortic valve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Non-compaction cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eosinophilic oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Post-tussive vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="15" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ear infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="63" subjects_affected="16" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Procedural anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sports injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood albumin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>International normalised ratio abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ultrasound liver abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vitamin E deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="84" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mirum Clinical Trials</name_or_title>
      <organization>Mirum Pharmaceuticals</organization>
      <phone>650-667-4085</phone>
      <email>medinfo@mirumpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

